Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
The Food and Drug Administration (FDA) on Wednesday approved the updated version of Pfizer’s and Moderna’s COVID-19 vaccines for this upcoming respiratory viral season, but limited the approval to ...
GAITHERSBURG, Md., Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid ™ 2025-2026 Formula for the ...
Novavax (NVAX) announced that the U.S. Food and Drug Administration has approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results